Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | RECQL | P46063 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
| ▸ | USP2 | O75604 | 2/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.58 |
| ▸ | HTR2A | P28223 | 2/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.58 |
| ▸ | LCK | P06239 | 2/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | FYN | P06241 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | MME | P08473 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 6/20 | 0.54 |
| ▸ | CA1 | P00915 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8470026 | 1.00 | KDM6B (0.60) | KDM6BALOX15HIF1AHSD17B10KDM4E | |
| SCHEMBL34002 | 1.00 | KDM6B (0.60) | KDM6BALOX15HIF1AHSD17B10KDM4E | |
| Hydrochloric Acid SCHEMBL29670211 | 0.98 | KDM6B (0.58) | KDM6BALOX15HIF1AHSD17B10KDM4E | |
| Water SCHEMBL31607501 | 0.98 | KDM6B (0.58) | KDM6BALOX15HIF1AHSD17B10KDM4E | |
| Water SCHEMBL17747948 | 0.98 | KDM6B (0.58) | KDM6BALOX15HIF1AHSD17B10KDM4E | |
| Water SCHEMBL29360651 | 0.98 | KDM6B (0.58) | KDM6BALOX15HIF1AHSD17B10KDM4E | |
| Water SCHEMBL31413328 | 0.98 | KDM6B (0.58) | KDM6BALOX15HIF1AHSD17B10KDM4E | |
| Hydrochloric Acid SCHEMBL523205 | 0.98 | KDM6B (0.58) | KDM6BALOX15HIF1AHSD17B10KDM4E | |
| Water SCHEMBL31482262 | 0.98 | KDM6B (0.58) | KDM6BALOX15HIF1AHSD17B10KDM4E | |
| Hydrochloric Acid SCHEMBL6825737 | 0.97 | KDM6B (0.57) | KDM6BALOX15HIF1AHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| US-20240058283-A1 | THE MODE OF ACTION OF N-MeDCPA ON TRPC CHANNELS | WEST VIRGINIA UNIV BOARD OF GOVERNORS ON BEHALF OF WEST VIRGINIA UNIV (US) | 2024-02-22 | — | — | US | claimed |
| WO-2023192319-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA (US) | 2023-10-05 | — | — | WO | claimed |
| EP-3618813-B1 | IMPROVED EXTENDED RELEASE HIGHLY LOADED DRUG COMPOSITIONS | LUBRIZOL ADVANCED MAT INC (US) | 2022-07-06 | — | — | EP | claimed |
| US-7989007-B2 | Weight loss composition | VINCENT JAMES ENTERPRISES, LLC (US) | 2011-08-02 | — | — | US | claimed |
| US-20090214680-A1 | Weight Loss Composition | INVIVO BEVERAGES LLC | 2009-08-27 | — | — | US | claimed |
| WO-2009006366-A2 | WEIGHT LOSS COMPOSITION | VINCENT JAMES ENTERPRISES, LLC (US) | 2009-01-08 | — | — | WO | claimed |
| EP-0484437-A4 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1994-06-01 | — | — | EP | claimed |
| EP-0484437-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. Searle & Co. (US) | 1992-05-13 | — | — | EP | claimed |
| US-12564596-B2 | Agents and methods for modulating pathogen activity | GRIFFITH UNIVERSITY (AU) | 2026-03-03 | — | — | US | disclosed |
| EP-4642415-A1 | FLAT ROUND TABLET FEEDING SYSTEM FOR UNIGEL CAPSULE PRODUCTION, WITHOUT THE USE OF MEDICINE PREFILLING SYSTEM | Procaps SA (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250295713-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES | DERMBIONT, INC. | 2025-09-25 | — | — | US | disclosed |
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | disclosed |
| US-20090137834-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| WO-2009006366-A2 | WEIGHT LOSS COMPOSITION | VINCENT JAMES ENTERPRISES, LLC (US) | 2009-01-08 | — | — | WO | disclosed |
| EP-0512848-B1 | Enzymatic resolution of alpha-tertiary carboxylic acid esters | GENZYME CORP (US) | 1999-07-21 | — | — | EP | disclosed |
| US-5492830-A | CONTACTING RACEMIC ESTER IN AQUEOUS MEDIUM WITH SERINE CARBOXYPEPTIDASE TO HYDROLYZE S-ENANTIOMER PREFERENTIALLY | GENZYME CORPORATION (US) | 1996-02-20 | — | — | US | disclosed |
| US-5202260-A | Partial hydrolysis, separation | GENZYME CORPORATION (US) | 1993-04-13 | — | — | US | disclosed |
| EP-0512848-A2 | Enzymatic resolution of alpha-tertiary carboxylic acid esters | GENZYME CORPORATION (US) | 1992-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240058283-A1 | THE MODE OF ACTION OF N-MeDCPA ON TRPC CHANNELS | TRPC4, TRPC3, TRPC1 | KDM6B 2998/4885ALOX15 3637/4885HIF1A 2136/4885 |
| US-12564596-B2 | Agents and methods for modulating pathogen activity | C3AR1, HTR3A, CHRM3 | KDM6B 4105/4885ALOX15 3036/4885HIF1A 1764/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | KDM6B 1256/4885ALOX15 3873/4885HIF1A 1784/4885 |
| US-20090137834-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | COMT, DDT, DDC | KDM6B 885/4885ALOX15 986/4885HIF1A 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.